Comparison Chart Actinium Pharmaceuticals, Inc.

Stocks

ATNM

US00507W2061

Biotechnology & Medical Research

Market Closed - NYSE 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
1.520 ^USD	-5.00%		+34.51%	+11.76%

10-23	Actinium Pharmaceuticals, Inc. Highlights First-In-Human Phase 1 Study of Atnm-400 A Her3-Targeted Non-Psma Radiotherapy in Prostate Cancer At Esmo 2026	CI
10-20	Actinium Pharmaceuticals, Inc. Unveils Atnm-400 Data At Eanm 2026 with First-In-Human Her3-Targeted Radiotherapy Approach Beyond Psma in Prostate Cancer	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	ACTINIUM PHARMACEUTICALS, INC.	Bio Therapeutic Drugs	-5.00%	+34.51%	+11.76%	+6.29%	-81.58%	43.39M